These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11685111)

  • 1. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.
    Haque T; Taylor C; Wilkie GM; Murad P; Amlot PL; Beath S; McKiernan PJ; Crawford DH
    Transplantation; 2001 Oct; 72(8):1399-402. PubMed ID: 11685111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
    Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children.
    Chiou FK; Beath SV; Wilkie GM; Vickers MA; Morland B; Gupte GL
    Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29388302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001; 72: 1399.
    Khanna A
    Transplantation; 2001 Oct; 72(8):1352-3. PubMed ID: 11685102
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
    Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
    Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders.
    Gandhi MK; Wilkie GM; Dua U; Mollee PN; Grimmett K; Williams T; Whitaker N; Gill D; Crawford DH
    Am J Transplant; 2007 May; 7(5):1293-9. PubMed ID: 17425621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes.
    Bourgault I; Gomez A; Gomard E; Levy JP
    Clin Exp Immunol; 1991 Jun; 84(3):501-7. PubMed ID: 1646086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases.
    Aspord C; Laurin D; Richard MJ; Vie H; Chaperot L; Plumas J
    Am J Transplant; 2011 Dec; 11(12):2613-26. PubMed ID: 21883919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
    Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
    Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease.
    McAulay KA; Haque T; Urquhart G; Bellamy C; Guiretti D; Crawford DH
    J Immunol; 2009 Mar; 182(6):3892-901. PubMed ID: 19265169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
    Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; Viganò M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
    Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.
    Emanuel DJ; Lucas KG; Mallory GB; Edwards-Brown MK; Pollok KE; Conrad PD; Robertson KA; Smith FO
    Transplantation; 1997 Jun; 63(11):1691-4. PubMed ID: 9197369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
    Hoffmann T; Russell C; Vindelov L
    APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.